RxSight, Inc.
RXST
NASDAQ·Healthcare·Medical - Devices·Mkt cap $291.8M
$7.05
▲ +6.66%
P/E
-6.24
Mkt Cap
$291.8M
52-Wk Range
$4.48–$13.22
52-Week Range
$4.48 - $13.22
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 19.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary light adjustable lens technology with patent protection
- Non-invasive post-operative customization capability unavailable from competitors
- Established relationships with cataract surgeons and ophthalmology practices
- Regulatory clearance and market presence in US and international markets
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Expanding adoption among cataract surgeons seeking premium outcomes and patient differentiation
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Hot
+32.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying RXST right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of -$0.29 vs -$0.33 consensus (+11.9% surprise). Revenue of $33.7M vs $32.5M expected (+3.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+11.9%
Revenue trend · last 8Q
—
+41%
+28%
-4%
-33%
-19%
-18%
+0%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$45.4M
$40.2M
$37.9M
$33.6M
$30.3M
$32.6M
$30.9M
$33.7M
Margins · last 8Q
Gross
76.7%
Operating
-40.8%
Profit
-35.9%
Wall Street consensus
3 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
67%
Sell
0%
Median Price Target
—
Latest: Needham · $11.00 · May 7, 2026
vs Industry
How RXST stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related